Cholinergic Receptor Nicotinic Beta Subunit 1 (CHRNB1) encodes the β1 subunit of the nicotinic acetylcholine receptor (nAChR). CHRNB1 is a critical component of muscle-type nAChRs, which mediate neuromuscular transmission at the motor endplate and are essential for voluntary muscle contraction. While primarily studied in the context of myasthenia gravis and congenital myasthenic syndromes, emerging research suggests cholinergic signaling dysfunction may contribute to neurodegenerative processes in the central nervous system.
| Property | Value |
|---|---|
| Symbol | CHRNB1 |
| Alternative Symbols | ACHRB, nAChRβ1 |
| Chromosome | 17p13.1 |
| Category | Ion Channel / Receptor |
| Protein Family | Cys-loop receptor superfamily |
CHRNB1 encodes the β1 subunit, which combines with α1, δ, and ε/γ subunits to form the muscle-type nAChR. Each nAChR consists of five subunits arranged around a central ion channel pore:
Cholinergic signaling is fundamentally linked to AD pathogenesis:
Basal forebrain degeneration — AD is characterized by loss of cholinergic neurons in the basal forebrain, which project to hippocampus and cortex. CHRNB1 expression in these regions may be affected[1:1].
Cognitive decline — Cholinergic signaling is critical for attention, learning, and memory. nAChR dysfunction may contribute to cognitive deficits.
Amyloid interaction — Amyloid-beta peptides can modulate nAChR function, potentially disrupting cholinergic signaling.
Therapeutic implications — Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) remain foundational AD treatments, highlighting the importance of cholinergic pathways.
Dopaminergic-cholinergic balance — In the basal ganglia, dopamine and acetylcholine operate in opposition. nAChR modulation may affect this balance in PD[2].
Levodopa-induced dyskinesias — Nicotinic agonists may reduce dyskinesias in PD models.
Neuroprotection — Nicotinic receptor activation may provide neuroprotective effects in dopaminergic neurons.
While not a neurodegenerative disease per se, MG demonstrates how autoantibodies against nAChRs cause profound muscle weakness:
CHRNB1 mutations can cause: